All posts by medical

Cell Biology

Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium – BioSpace

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that data revealing novel mechanistic attributes of its lead candidate PT-112, an immunogenic cell death (ICD) inducer under Phase 2 development, will be presented at the 32nd Symposium of the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) taking place virtually from October 24-25.

Title:

PT-112, A First-In-Class Pyrophosphate-Platinum Conjugate, Selectively Targets Highly Glycolytic Tumor Cells (catalog number 188)

Abstract availability:

Saturday, October 24, 2020 on EORTC-NCI-AACR symposium site and on the Phosplatin Therapeutics web site

Session:

New Drugs Poster Session (code 380)

Lead Author:

A. Anel, University of Zaragoza /Aragn Health Research Institute, Biochemistry and Molecular and Cell Biology, Zaragoza, Spain

Building upon prior publication of the ICD effects of PT-112, the body of work to be presented is part of an effort to understand the metabolic pathways and cellular targets affected by PT-112 upstream of ICD initiation. "The data to be reported at the 32nd EORTC-NCI-AACR Virtual Symposium advance the body of knowledge around PT-112's pleiotropic mechanism of action and provide valuable information on further potential clinical applications of PT-112. As we continue our clinical study of this unique compound in patients with challenging cancers, such insights are important," said Robert Fallon, co-founder and chief executive officer, Phosplatin Therapeutics. "We are pleased to co-present this body of work under our fruitful collaboration with the Anel lab at the University of Zaragoza, Spain."

About PT-112

PT-112 is a novel small molecule conjugate of pyrophosphate that possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents the best-in-class small molecule inducer of this immunological form of cancer cell death and is currently under Phase II development. The rst in-human study of PT-112 demonstrated an attractive safety prole and evidence of long-lasting responses among heavily pre-treated patients and won "Best Poster" within the Developmental Therapeutics category at the ESMO 2018 Annual Congress. The novelty of PT-112's pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in or metastasize to the bone. The combination Phase Ib study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO 2020 Virtual Congress.

About Phosplatin Therapeutics

Phosplatin Therapeutics is a privately held, clinical stage pharmaceutical company that holds exclusive global license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with chemotherapeutic regimens. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death and osteotropism. Clinical data generated to date across three Phase I studies have demonstrated single-agent anti-cancer activity and an attractive tolerability prole, and two Phase II studies of PT-112 are underway. The company's research and development work to date has spanned fteen countries and been funded by private investors and family investment ofces in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company sponsors the ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pzer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada).

CONTACTS:

Phosplatin TherapeuticsTaylor YoungSenior Director of Strategic DevelopmentTel: +1 646 380 2441Email: tyoung@phosplatin.com

Westwicke, an ICR CompanyInvestors:Stephanie CarringtonTel: +1 646 277 1282Email: Stephanie.Carrington@westwicke.com

Media:Mark CorbaeTel: +1 203 682 8288Email: mark.corbae@westwicke.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/phosplatin-therapeutics-announces-presentation-of-research-into-pt-112-mechanism-of-action-at-the-32nd-eortc-nci-aacr-virtual-symposium-301155292.html

SOURCE Phosplatin Therapeutics

Excerpt from:
Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium - BioSpace

Cell Biology

Anti-age your immune system here’s how to turn back the clock – The Times

As with nearly everything else to do with our bodies, the effectiveness of the immune system declines with age. From our twenties onwards the bodys ability to fight infection decreases at a rate of about 2 to 3 per cent a year, gradually leaving us more susceptible to diseases, says Janet Lord, a professor of immune cell biology and the director of the Institute for Inflammation and Ageing at Birmingham University. But, she says, the speed at which this happens is not unavoidable. Ill health should not be an inevitable part of growing old. By understanding what happens to our immune systems as we age, we can break that link.

Ageing of the immune system is accelerated by the usual baddies, smoking, a sedentary lifestyle,

Read the original here:
Anti-age your immune system here's how to turn back the clock - The Times

Cell Biology

Study reports chemical mechanism that boosts enzyme observed in cancer – Newswise

Newswise A new study led by scientists at IUPUI and Indiana University Bloomington is the first to describe a biochemical mechanism that increases the activity of a molecule whose presence is observed in many types of cancer.

The molecule, an enzyme called Pif1helicase, plays a role in many important cellular processes in the body. Tightly regulating this protein is vital to genome stability because too little -- or too much -- activity can influence aging and age-related diseases, primarily cancer. A common cancer therapy, HDAC inhibitors, can also trigger a spike in this enzyme.

"Currently, we're giving people drugs that increase Pif activity without fully knowing how it affects other parts of the cell that play a role in genome stability," said Lata Balakrishnan, an associate professor of biology in the School of Science at IUPUI, who is co-lead author on the study.

"HDAC inhibitors upregulate certain tumor-suppression genes, and therefore are used in combination therapies to treat specific cancers, but when it comes to their impact on other parts of the cell, we're basically operating in the dark."

The study's other lead author is Matthew Bochman, an associate professor in the IU Bloomington College of Arts and Sciences' Department of Molecular and Cellular Biochemistry. Other co-authors are Christopher Sausen and Onyekachi E. Ononye, Ph.D. students in Bochman's and Balakrishnan's labs, respectively, at the time of the study.

The mechanism described in the study is the effect of lysine acetylation on Pif1. Lysine acetylation occurs when a small molecule called an acetyl group binds to lysine, an amino acid used to build common proteins in the body. This action transforms lysine from a positively charged molecule to a neutrally charged molecule. This neutralization can impact protein function, protein stability and protein-protein interaction in cells, among other things.

Helicases are known as the genetic "zippers" of cells because they pull apart DNA for the purpose of genetic replication and repair. They also help maintain telomeres, the structure at the end of chromosomes that shorten as people age.

In the new study, the researchers identified lysine acetylation on Pif1 helicase and showed the addition of the acetyl group increases the protein's activity -- as well as its "unzipping" function. They also found that lysine acetylation changes the shape -- or "conformation" -- of the Pif1 protein. They believe that this shape change increases the amount of Pif1 helicase.

"The dynamic interplay of the addition and removal of the acetyl group on lysine regulates a wide variety of proteins within the cell," Balakrishnan said. "Perturbations to this process can play a role in cancer, aging, inflammatory responses and even addiction-related behaviors."

"As a class, helicases are involved in a lot of processes necessary for genome integrity," Bochman added. "Any significant failure in these processes is generally carcinogenic."

The precise details of lysine acetylation in Pif1, its effect of the enzyme's shape and the resulting impact on helicase activity took nearly five years to observe and report. The study, carried out in parallel on two IU campuses, was made possible by the lead scientists' complementary expertise. As a biochemist who has previously studied lysine acetylation in other proteins, Balakrishnan was able to isolate Pif1 in vitro to observe its response to chemical reactions in a test tube. In contrast, as a geneticist working in yeast as a model organism to study Pif1, Bochman was able to modify cells in vivo to watch reactions play out in a living organism.

"The ability to observe these reactions in a living cell is often more relevant, but it's also a lot messier," Balakrishnan said. "Our experiments were constantly informing each other as to where to go next.

Looking to the future, Bochman said intricate knowledge of cellular processes -- such as lysine acetylation -- will increasingly play a role in personalized therapy.

"If you sequence a patient's tumor, you can fine-tune drugs to target very specific enzymes," he said. "Instead of a drug that broadly affects the whole cell, it will be possible to take a targeted approach that reduces potential side effects. This level of personalization is really the future of cancer biology and cancer medicine."

"Lysine Acetylation Regulates the Activity of Nuclear Pif1" is available online in advance of print in the Journal of Biological Chemistry. A perspective article on the work is also forthcoming in the journal Current Genetics.

This work was supported in part by the National Science Foundation and the American Cancer Society.

IU Research

Indiana University's world-class researchers have driven innovation and creative initiatives that matter for 200 years. From curing testicular cancer to collaborating with NASA to search for life on Mars, IU has earned its reputation as a world-class research institution. Supported by $854 million last year from our partners, IU researchers are building collaborations and uncovering new solutions that improve lives in Indiana and around the globe.

See more here:
Study reports chemical mechanism that boosts enzyme observed in cancer - Newswise

Cell Biology

Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development – PRNewswire

TORONTO, Oct. 19, 2020 /PRNewswire/ --Notch Therapeutics Inc., a cell therapy company with a proprietary platform for generating renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Kamran Alam as Executive Vice President, Finance and Chief Financial Officer and Gregory Block as Senior Vice President, Corporate Development, effective immediately.

"Adding these experienced leaders to our team underpins our strategy of advancing our pipeline and supporting our partnering initiatives," said David Main, President and Chief Executive Officer of Notch. "Their combined expertise in financial and corporate strategy will augment our deep technical team as we advance our proprietary platform that enables the development of highly consistent T cell therapies manufactured at industrial scale and lower cost. We look forward to their contributions as members of our executive team."

Kamran Alam, Executive Vice President, Finance and Chief Financial OfficerKamran Alam brings to Notch more than 20 years of global corporate finance and business development leadership experience. He joins Notch from Neoleukin Therapeutics, where he served as Interim Chief Financial Officer following Neoleukin's merger in 2018 with Aquinox Pharmaceuticals. Previously, in his role as Chief Financial Officer and Vice President, Finance at Aquinox, Mr. Alam provided finance leadership for the company's IPO on the NASDAQ stock exchange in 2014. Prior to his tenure with Aquinox, Mr. Alam held senior roles in business development for a number of biotechnology and pharmaceutical companies. Mr. Alam is a Chartered Professional Accountant. He holds a B.Sc. in Cell Biology and Genetics from the University of British Columbia and an M.B.A. in International Business and Strategy from the University of Victoria.

Gregory Block, Ph.D., Senior Vice President, Corporate DevelopmentGregory Block is a seasoned biotechnology executive with more than 10 years of experience in the development and commercialization of novel therapeutic modalities. Prior to his position with Notch, he served as Director of Business Development for Astellas Pharmaceuticals, where he led business development and strategic initiatives for regenerative medicine and cell therapy immune oncology. Dr. Block joined Astellas via the company's 2018 acquisition of Universal Cells Inc., where he was instrumental in company-building and business development. Dr. Block holds a Ph.D. in Molecular Biology from Tulane University and completed a fellowship at the University of Washington.

About Notch Therapeutics (www.notchtx.com)Notch Therapeutics is a cell therapy company that has unlocked the ability to produce T cells and other cells from any source of stem cells. At the core of the Notch technology is the Engineered Thymic Niche (ETN) platform, which enables precision control of cell fate during the differentiation and expansion of stem cells. The ETN is the first technology that can reliably generate T-cells from iPSC-derived progenitor cells using fully defined, non-xenogenic reagents at industrial scale. By leveraging the ETN platform, Notch is positioned to design and deliver the next generation of T cell therapeutics that are specifically engineered to address the underlying biology of complex disease systems. The technology was invented in the laboratories of Juan-Carlos Ziga-Pflcker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM) in Toronto.

Contact:Mary MoynihanM2Friend Biocommunications802-951-9600[emailprotected]

SOURCE Notch Therapeutics

Follow this link:
Notch Therapeutics Strengthens Leadership Team with Appointment of Kamran Alam as CFO and Gregory Block as SVP, Corporate Development - PRNewswire

Cell Biology

Sheffield scientists help to identify common vulnerabilities in Covid-19 and other lethal coronaviruses – University of Sheffield News

15 October 2020

Scientists from the University of Sheffield are working with almost 200 researchers from across the globe to identify vulnerabilities in three lethal coronaviruses - including SARS-CoV-2 responsible for the Covid-19 pandemic.

The international team of experts from 14 leading institutions have studied SARS-CoV-2, SARS-CoV-1 and MERS-CoV to identify commonly hijacked cellular pathways and detect promising targets for broad coronavirus inhibitors with high barriers to resistance. This important research paves the way in identifying a successful treatment for Covid-19.

Using the molecular insights from the study, the researchers also analysed medical records of approximately 740,000 patients with Covid-19 to examine drugs which are already approved for use and successful in treating other medical conditions and could be deployed rapidly to help the clinical outcomes of these patients.

The findings, published in the prestigious journal Science, demonstrate how molecular information can be translated into real-word implications for the treatment of Covid-19, an approach that can ultimately be applied to other diseases in the future.

Dr Andrew Peden, from the University of Sheffields Department of Biomedical Science and one of the lead authors, said: "The new insights from this groundbreaking study have revealed potential targets that will help develop a first-of-its-kind therapy across all coronaviruses.

"In Sheffield we were able to bring our broad expertise, as well as the use of our world-class imaging facilities towards a common research goal to desperately find an effective treatment for Covid-19.

"This study truly demonstrates what can be achieved over a relatively short period of time when scientists openly share ideas, facilities and work for the common good."

Dr Pedens team used their expertise in cell biology and advanced microscopy to localise every major viral protein encoded by SARS-CoV-2, SARS-CoV-1 and MERS-CoV inside human cells.

They found that many of the conserved proteins have similar localisations suggesting that they hijack the same cellular processes.

In addition, they also identified that the viral protein Orf9b is localised to mitochondria and alters the levels of Tom70, a key protein which helps cells identify if they have been infected by viruses.

This research, in collaboration with work performed in Freiburg, Paris and San Francisco provides a molecular framework which in the longer term will help in the development of new antiviral therapies which are desperately needed to treat Covid-19.

Dr Andrew Peden, Dr Dan Williams and Miss Amber Shun-Shion are funded by grants from the Biotechnology and Biological Sciences Research Council (BBSRC). All of the imaging studies for this investigation were performed at the Wolfson Light Microscopy Facility at the University of Sheffield.

Professor Colin Bingle from University of Sheffields Department of Infection, Immunity and Cardiovascular Disease, said: This systematic cell biology paper used a functional genetic screening approach using real world patient data, to identify potential drugs that can be investigated as treatments for COVID-19. The multinational collaborative nature of this study exemplifies the way that the biomedical community has come together to fight this deadly pandemic."

The Department of Biomedical Science carries out world-leading research to understand disease, improve treatments, and find potential cures. Researchers are working in areas ranging from cell biology and developmental biology to neuroscience and regenerative medicine, with expertise in topics including stem cells and cancer. Pioneering projects have led to breakthroughs in applying ultrasound to treat wounds, using human stem cells to treat hearing loss, and the generation of animal models for neurodegenerative diseases, schizophrenia, muscular dystrophy and cancer. Find out more at http://www.sheffield.ac.uk/bms.

The University of Sheffield

With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the worlds leading universities.

A member of the UKs prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.

Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.

Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education.

Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.

Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.

For further information please contact:

Amy HuxtableMedia Relations OfficerThe University of Sheffield0114 222 9859a.l.huxtable@sheffield.ac.uk

Read the original:
Sheffield scientists help to identify common vulnerabilities in Covid-19 and other lethal coronaviruses - University of Sheffield News

Cell Biology

Natural Infant Formula On The Horizon: How To Copy What Nature Put In Mothers Milk – Forbes

Novel ingredients that are built with biology

Photo by Lucy Wolski on Unsplash

Synthetic biology has already created a world of new foods that would have sounded impossible not so long ago. Today you can sink your teeth into a plant-based burger that bleeds with vegan cheese, then enjoy cow-free dairy ice cream for dessert. But what if bioengineering could make nutrition not just healthier and more humane, but more naturalcloser to original biology?

Of all the milk produced by mammals, human milk is the most complex. Refined over millions of years of evolution, it contains more than 200 unique sugars for infant nutrition, quadruple that of the 50 in cows milk. Studies of breastfeeding show that mothers milk plays a key role in boosting infant nutrition, immune system development, and gut health. In the modern era, however, breastfeeding is not always an option for caregivers.

Thats why the gold standard of infant formula is to create a product as similar to breast milk as possible, so babies can get the complex blend of nutrients that were tailored for them by nature. Thats exactly what Conagen has accomplished, again, with two synthetic biology breakthroughs that bring infant formula even closer to actual human milk.

Earlier this year, I wrote about Conagens breakthrough production of lactoferrin, a milk protein crucial to infant nutrition. Now, Conagen is tackling two more compounds found in breast milk: naturally occurring complex sugars called human milk oligosaccharides (HMOs), and a tasteless, odorless fatty acid called FBA that supports gut and immune system development. After lactoferrin, these are Conagens second and third offerings for fortifying infant formula.

HMOs serve an important signaling function in a newborns body: they help the young immune system tell the difference between dangerous foreign bodies, such as bacteria, and beneficial nutrients from food. The immune systems ability to distinguish friend from foe is what prevents the emergence of food allergies at a young age. Meanwhile, FBA promotes the production of butyrate, a pre- and postbiotic that supports healthy cellular development of the gut lining.

If mothers milk came with a nutrition facts label, HMOs would be the fourth ingredient after water, fat, and lactose. The most prevalent HMO in mothers milk is known as 2-FL. Because this HMO is not found in cows milk, infant formula needs to be supplemented with lab-made 2-FL. Producing 2-FL has required the use of genetically modified organisms (GMOs)until now.

In a process similar to how cheese is made by adding enzymes to milk, Conagen uses bioconversion to synthesize and then purify 2-FL. Unlike its competitors, Conagen can perform this chemistry outside of a living cell. This results in a more reliable and streamlined production process.

For Casey Lippmeier, VP of innovation at Conagen, reproducing the benefits of natural mothers milk is a personal goal. A father and a scientist, Dr. Lippmeier has been studying how to improve infant formula for his entire career. Mothers who dont have any other option than to use formula can feel better and better with every new improvement we make on health, he says. Manufacturers can expect Conagens HMOs to be available in the next few months, or partner with Conagen in the licensing of FBAs for other applications.

From pharmaceuticals to supplements to flavors, Conagens fermentation process has already put synthetic biology on the map within industrial manufacturing. Now, with its latest human milk compounds, the company continues to bring infant formula closer to the optimal nutrition of mothers milk. A healthier world for every newborn: thats building a better world with biology.

Subscribe to my weekly synthetic biology newsletter. Thank you to Desiree Ho for additional research and reporting in this article. Im the founder of SynBioBeta, and some of the companies that I write about, including Conagen, are sponsors of the SynBioBeta Global Synthetic Biology Summit and digest.

Read the rest here:
Natural Infant Formula On The Horizon: How To Copy What Nature Put In Mothers Milk - Forbes

Cell Biology

Scientists uncover important disease-fighting role for cells in the liver – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Oct 19 2020

Scientists at Scripps Research have uncovered an important disease-fighting role for cells called hepatocytes, which constitute most of the liver. The discovery could potentially be harnessed to develop new medicines for viral illnesses.

According to the new study, which appears in Communications Biology, hepatocytes help control infections from common viruses called coxsackieviruses, and probably defend against many other viruses as well. The findings suggest these liver cells, long known for their role in deactivating chemical toxins in the blood, should also be viewed as a significant element of the immune system--an element that future drugs might be able to enhance to strengthen the body's defense against emergent viruses.

Hepatocytes may have evolved the ability to absorb and silence a variety of different viruses, to slow their spread in the body and reduce infection-related illness."

Taishi Kimura, PhD, postdoctoral research associate at Scripps Research and first author of the study

Kimura worked on the study while in the laboratory of J. Lindsay Whitton, MD, PhD, professor in the Department of Immunology and Microbiology at Scripps Research and senior author of the study.

Whitton and his lab have long studied coxsackieviruses, a family of polio-like viruses that spread via the fecal-oral route and can cause a broad array of symptoms including fever, sore throat, rash, diarrhea, meningitis, pancreatitis and inflammation of the heart muscle. The viruses are named for the New York town of Coxsackie, where virus specimens were initially isolated from patients in the late 1940s.

Recently Kimura and research assistant Claudia Flynn observed that mice experience significant liver damage, including damage to and deaths of hepatocytes, when infected with a type of coxsackievirus called coxsackievirus B3 (CVB3).

Hepatocytes, along with many other cell types, express a cell-surface protein called "coxsackievirus-adenovirus receptor" or CAR, which CVB3 uses to get into cells. So Kimura and Flynn genetically engineered mice whose hepatocytes--but no other cell types--lack CAR, and thus could not be infected by CVB3. Unsurprisingly, when these mutant mice were infected with CVB3, their hepatocytes were spared significant damage.

However, the CVB3 infection hit these mutant mice much harder on the whole, compared with non-mutant siblings. The mutants with protected hepatocytes swiftly showed high blood levels of virus, lost more weight, developed complications such as heart inflammation and were much more likely to die from the infection.

These findings showed that ordinary hepatocytes, when they are able to be infected by CVB3, help protect the rest of the body from the virus. In further experiments, the team found more support for this idea, observing that when hepatocytes absorb CVB3, they quickly shut down the virus's replication using an immune protein called IRF1. Although the infected hepatocytes are damaged by taking up the virus, the liver itself does not show the strong inflammation that is seen in other virus-infected organs, such as the heart and pancreas.

Virus researchers have known that other, much-less numerous cell types in the liver--such as so-called Kupffer cells--can trap and neutralize viruses that are circulating in the blood. Hepatocytes had not been thought to do this, but the study shows that they do.

Given the large size of the liver, hepatocytes constitute a major cell type in the body. To the researchers, it seems unlikely that this major cell type has evolved to defend against only one family of viruses. More likely, they say, it acts broadly, like an antiviral "sponge," soaking up any of a variety of virus types from the bloodstream early in infection, to help slow and limit the infection in the rest of the body. Hepatocytes that absorb viruses in this way may be damaged or die, the researchers add, but the harm to the liver is perhaps only temporary.

"Hepatocytes have an extraordinary capacity for regeneration, and this may be an adaptation that has more to do with their antiviral role than with their better-known role against toxins," Whitton says. "Toxins may not have been enough of a threat during animal evolution to create pressure for such an adaptation, but viruses probably have been."

Whitton and Kimura also note that other common viruses, including the SARS-CoV-2 coronavirus that causes COVID-19, can cause modest and often temporary liver damage, much like that observed for CVB3. This again hints that hepatocytes' defensive role may extend far beyond coxsackieviruses. Though Whitton is retiring this year, Kimura intends to continue this line of research into whether--and how--hepatocytes defend against SARS-CoV-2 and other viruses.

"The protein IRF1, which hepatocytes use to silence CVB3, works by activating a broad set of antiviral genes, and it may be that each of these antiviral genes is adapted to silence a different set of viruses," Whitton says.

By actively taking up virus that is circulating in the blood, hepatocytes may also serve as a first-alert mechanism that helps activate other immune system elements, Kimura says. In principle, Kimura adds, future drug treatments might enhance hepatocytes' uptake of viruses to limit serious infections when no other option is available, such as with new human-infecting viruses.

"This hepatocyte response might turn out to be a key element of the human immune response against emergent viruses," he says.

Source:

Journal reference:

Kimura, T., et al. (2020) Hepatocytes trap and silence coxsackieviruses, protecting against systemic disease in mice. Communications Biology. doi.org/10.1038/s42003-020-01303-7.

More here:
Scientists uncover important disease-fighting role for cells in the liver - News-Medical.Net

Neuroscience

Healthgrades Honors Dignity Health Inland Empire hospitals for top performance in Critical Care, Neuroscience and Orthopedics – The Inland Empire…

Dignity Health Community Hospital of San Bernardino and Dignity Health St. Bernardine Medical Center announced today that the hospitals are named 2021 Five-Star Recipients in Critical Care, Heart Care, Orthopedics and Pulmonary procedures by Healthgrades, the leading online resource for comprehensive information about physicians and hospitals. Every year, Healthgrades evaluates hospital performance at nearly 4,500 hospitals nationwide for 34 of the most common inpatient procedures and conditions.*

Were honored to be recognized by Healthgrades for the outstandingquality care we provide to the San Bernardino community, states DouglasKleam, Hospital President, St. Bernardine Medical Center. These awards reflect our high standards of providing safe,compassionate care with excellent clinical outcomes.

Specifically, Healthgrades recognized St.Bernardine Medical Center as a:

AFive-Star rating indicates that statistically the hospitals clinical outcomesare significantly better than expected when treating the condition orperforming the procedure being evaluated.

According to June Collison, Hospital Presidentat Community Hospital, Our skilled care team of nurses and doctors whodeliver exceptional services to our patients deserve this recognition and it isrewarding to have our top-quality care honored by Healthgrades.

Community Hospital of San Bernardino has beennamed a:

Dignity Healths achievements are part of the findings featured in Healthgrades2021 Report to the Nation. The new report demonstrates how clinical performance continues to differ dramatically between hospitals regionally and nationally. Clinical quality varies significantly between hospitals, so its important for consumers to use information about outcomes to assess where to receive care, said Brad Bowman, MD, Chief Medical Officer at Healthgrades. These Five-Star ratings for critical care, neuroscience, and orthopedic procedures showcase the expertise and commitment of the San Bernardino hospitals to the patients they serves.

*For its analysis, Healthgrades evaluatedapproximately 45 million Medicare inpatient records for nearly 4,500 short-termacute care hospitals nationwide to assess hospital performance in 32 commonconditions and procedures, and evaluate outcomes in appendectomy and bariatricsurgery using all-payer data provided by 17 states. Healthgrades recognizes ahospitals quality achievements for cohort-specific performance, specialty areaperformance, and overall clinical quality. Individual procedure or conditioncohorts are designated as 5-star (statistically significantly better thanexpected), 3-star (not statistically different from expected) and 1-star(statistically significantly worse than expected) categories. The complete Healthgrades2021 Report to the Nation and detailed study methodology, can be foundat http://www.healthgrades.com/quality

Here is the original post:
Healthgrades Honors Dignity Health Inland Empire hospitals for top performance in Critical Care, Neuroscience and Orthopedics - The Inland Empire...

Neuroscience

Neuroscience Technologies Market : Drivers, Restraints, Opportunities, and Threats (20202025) – The Think Curiouser

The latest published an effective statistical data titled as Neuroscience Technologies Market. It defines about the recent innovations, applications and end users of the market. It covers the different aspects, which are responsible for the growth of the industries. Different domains are considered on the basis of the capital of Neuroscience Technologies market. The analyst examines different companies on the basis of their productivity to review the current strategies. All leading players across the globe, are profiled with different terms, such as product types, industry outlines, sales and much more.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2717514&source=atm

The study throws light on the recent trends, technologies, methodologies, and tools, which can boost the performance of companies. For further market investment, it gives the depth knowledge of different market segments, which helps to tackle the issues in businesses. It includes effective predictions about the growth factors and restraining factors that can help to enlarge the businesses by finding issues and acquire more outcomes. Leading market players and manufacturers are studied to give a brief idea about competitions. To make well-informed decisions in Neuroscience Technologies areas, it gives the accurate statistical data.

The analyst also focuses on economic and environmental factors, which impacts on the growth of the businesses. For global analysis, the market is examined by considering the different regions such as North America, Latin America, Japan, China, and India. Leading companies are focusing on spreading their products across the regions. Research and development activities of the various industries are included in the report, to decide the flow of the market.

The major players profiled in this report include:BDAbbottMedtronic

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2717514&source=atm

Competition Analysis

This report examines the ups and downs of the leading key players, which helps to maintain proper balance in the framework. Different global regions, such as Germany, South Africa, Asia Pacific, Japan, and China are analyzed for the study of productivity along with its scope. Moreover, this report marks the factors, which are responsible to increase the patrons at domestic as well as global level.

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-General Type

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Neuroscience Technologies for each application, including-ResearchTherapeutics

It gives a detailed description of drivers and opportunities in Neuroscience Technologies market that helps the consumers and potential customers to get a clear vision and take effective decisions. Different analysis models, such as, Neuroscience Technologies are used to discover the desired data of the target market. In addition to this, it comprises various strategic planning techniques, which promotes the way to define and develop the framework of the industries.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2717514&licType=S&source=atm

The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Neuroscience Technologies market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

The content of the study subjects, includes a total of 15 chapters:

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Neuroscience Technologies Market Analysis, Trends, Growth Factor

Chapter 5 Neuroscience Technologies Market Application and Business with Potential Analysis

Chapter 6 Global Neuroscience Technologies Market Segment, Type, Application

Chapter 7 Global Neuroscience Technologies Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Neuroscience Technologies Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Contact Us:

marketresearchhub

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

About marketresearchhub

marketresearchhub is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

The rest is here:
Neuroscience Technologies Market : Drivers, Restraints, Opportunities, and Threats (20202025) - The Think Curiouser

Neuroscience

Neuroscience Market | Global Industry Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2026 – TechnoWeekly

IndustryGrowthInsights has published a latest market research report on Neuroscience market. The report provides a comprehensive scope of the market which caters enterprise to take critical business decisions. It consists of changing market trends, latest developments, growth opportunities, challenges, and detailed competitive analysis about the emerging and behemoth market players. This market research report also includes complete regional outlook and highlights top winning strategies that has helped industry players to expand their market share.

Global Neuroscience Market report gives out an in-depth analysis of the market scenario and covers the segmentation of the market in an insightful manner. IndustryGrowthInsights has congregated a massive amount of the data after monitoring the market for considerable amount of period and prepared the report for the forecast period 2020-2027. This report explains about the supply and demand scenario and assesses the possible changes in the market with the help of graphical representation to personify more clarity about the market.

Request a sample before buying this report @ https://industrygrowthinsights.com/request-sample/?reportId=168030

Market Research Report Covers Impacts of COVID-19 To The Market.

The COVID-19 pandemic has dramatically changed the dynamics of the Neuroscience market. This market research report includes extensive data on the impacts of the market. The research analyst team of the firm have been monitoring the market during this coronavirus crisis and has been talking with the industry experts to finally publish a detailed analysis about the future scope of the market. They have followed a robust research methodology and got involved in the primary and secondary research to prepare the Neuroscience market report.

This market report comprises of possible revenue growth, potential lucrative opportunities, product ranges, pricing factors, and parameters to confer the emerging and new entrants in the industry with a structured market data. This report encompasses the crucial government policies and regulations that significantly controls the Neuroscience market. Moreover, it includes the recent business agreements, mergers, acquisitions, partnerships, and even fallouts to provide the industry players with complete overview of the Neuroscience market.

The prominent Companies Covered in the Market Report

GE HealthcareSiemens HealthineersNoldus Information TechnologyMightex BioscienceThomas RECORDING GmbHBlackrock MicrosystemsTucker-Davis TechnologiesPlexonPhoenix Technology GroupNeuroNexusAlpha OmegaNeuroscienc

*Note: Additional players can be included in the list

Market Segmentation

By Product Type

Whole Brain ImagingNeuro-MicroscopyElectrophysiology TechnologiesNeuro-Cellular ManipulationStereotaxic SurgeriesAnimal BehaviorOtherWhole Brain Imaging, Neuro-Microscopy, and Electrophysiology Technologies are the top three types of neuroscience, with a combined market share of 62%Neuroscienc

By Application

HospitalsDiagnostic LaboratoriesResearch InstitutesOtherNeuroscience is applied mostly in the hospital with a market share of 47%. It is followed by Research Institutes and Diagnostic Laboratories

As per the report, the Neuroscience market is projected to reach a value of USDXX by the end of 2027 and grow at a CAGR of XX% through the forecast period (2020-2027). The report describes the current market trend of the Neuroscience in regions, covering North America, Latin America, Europe, Asia Pacific, and Middle East & Africa by focusing the market performance by the key countries in the respective regions.

This market segmentation analysis is expected to help the enterprise to strategize their product development strategies and marketing strategies in the region accordingly. IndustryGrowthInsights also offers customization of the report and provide quarterly/yearly updates on the report to help the enterprise to bring their A game.

You can buy the complete report @ https://industrygrowthinsights.com/checkout/?reportId=168030

The following is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Neuroscience Market Overview

Global Neuroscience Market Analysis and Forecast by Type

Global Neuroscience Market Analysis and Forecast by Application

Global Neuroscience Market Analysis and Forecast by Sales Channel

Global Neuroscience Market Analysis and Forecast by Region

North America Neuroscience Market Analysis and Forecast

Latin America Neuroscience Market Analysis and Forecast

Europe Neuroscience Market Analysis and Forecast

Asia Pacific Neuroscience Market Analysis and Forecast

Asia Pacific Neuroscience Market Size and Volume Forecast by Application

Middle East & Africa Neuroscience Market Analysis and Forecast

Why should you buy this report from us?

Our dedicated research team will be available 24/5 to you. They have been tracking the market since 2015 which has tremendously helped them to curate the Neuroscience market report. IndustryGrowthInsights just does not provide current/future market analysis but provide the enterprise with potential market avenues and revenues which is an ultimate game changer for a company.

We collaboratively work with the industry delegates to tailor the report. Over the years, we have carried out several interviews with the industry experts to provide a wholesome scope of the market. This market research report provides data in a comprehensive form with help of tables, statistics, and infographics. It offers detailed insights of the market to make crucial decisions in accordance to the present and future market scenario.

IndustryGrowthInsights gives a 360 view of the market which includes high growth opportunities, pitfalls, risk factors, latest advancements, and market drivers that helps the enterprise to create business strategies accordingly. This market research report provides distribution channel assessments, clients customers insights, entry level strategy, and innovation trends.

About IndustryGrowthInsights

IndustryGrowthInsights has an extensive experience in the creation of tailored market research reports in several industry verticals. We cover in-depth market analysis which include producing creative business strategies for the new entrants and the emerging players of the market. We take care that our every report goes through intensive primary, secondary research, interviews, and consumer surveys. Our company provide market threat analysis, market opportunity analysis, and deep insights on the current and market scenario.

To provide the utmost quality of report, we invest in analysts that holds stellar experience in business domain and has excellent analytical and communication skills. Our dedicated team goes through quarterly training which helps them to acknowledge the latest industry practices and to serve the clients with foremost consumer experience.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://industrygrowthinsights.com

Read more from the original source:
Neuroscience Market | Global Industry Analysis By Trends, Size, Share, Company Overview, Growth And Forecast By 2026 - TechnoWeekly